Patents Issued in June 1, 2017
-
Publication number: 20170152237Abstract: The present invention provides a process for the treatment of a liquid first furan stream comprising furan and carbon monoxide, said process comprising the steps of: i) contacting said first furan stream with a CO-lean first gaseous stream; and ii) stripping at least a portion of the carbon monoxide in the first furan stream into the first gaseous stream to produce a second furan stream comprising less carbon monoxide than the first furan stream and a CO-enriched second gaseous stream.Type: ApplicationFiled: March 26, 2015Publication date: June 1, 2017Inventors: Sipke Hidde WADMAN, Jean Paul Andre Marie Joseph Ghislain LANGE
-
Publication number: 20170152238Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: ApplicationFiled: August 4, 2016Publication date: June 1, 2017Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas Neil Wheeler, Thomas L. Little
-
Publication number: 20170152239Abstract: This invention relates to compounds of general formula in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.Type: ApplicationFiled: February 6, 2017Publication date: June 1, 2017Applicant: Pfizer Inc.Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, Indrawan James MCALPINE, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES
-
Publication number: 20170152240Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.Type: ApplicationFiled: February 9, 2017Publication date: June 1, 2017Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
-
Publication number: 20170152241Abstract: The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.Type: ApplicationFiled: May 23, 2014Publication date: June 1, 2017Inventors: Jae Young SIM, Myung Hun CHA, Tae Kyun KIM, Young Ae YOON, Dong Hoon KIM
-
Publication number: 20170152242Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.Type: ApplicationFiled: May 12, 2015Publication date: June 1, 2017Applicant: TEIJIN PHARMA LIMITEDInventors: Akinobu MARUYAMA, Susumu TAKEUCHI, Yoshimasa TAKAHASHI
-
Publication number: 20170152243Abstract: Disclosed are polymorph of allisartan isoproxil and a pharmaceutical composition thereof. The polymorph is non-electrostatic, highly flowable and highly stable, and can be used for treating hypertension and complications thereof.Type: ApplicationFiled: June 5, 2015Publication date: June 1, 2017Inventors: Duanming Tan, Jun Ou
-
Publication number: 20170152244Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where R1 can be hydro, methoxy, difluoromethoxy or trifluoromethoxy; R2 can be hydro, methoxy, trifluoromethoxy or trifluoromethyl; and R3 can be hydro or methoxy. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: ApplicationFiled: November 23, 2016Publication date: June 1, 2017Applicants: AstraZeneca AB, Cancer Research Technology LimitedInventor: Maurice Raymond Verschoyle Finlay
-
Publication number: 20170152245Abstract: The present invention provides substituted benzimidazoles, pharmaceutical composition comprising the substituted benzimidazoles, and their use for preventing or treating a subject suffering from diseases or conditions associated with platelet activation aggregation and/or platelet activation.Type: ApplicationFiled: November 25, 2016Publication date: June 1, 2017Applicant: National Taiwan UniversityInventors: Tur-Fu Huang, Shiu-Wen Huang, Jin-Cherng Lien, Sheng-Chu Kuo
-
Publication number: 20170152246Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: September 9, 2016Publication date: June 1, 2017Inventors: Rajinder Singh, Kin Tso, Jing Zhang, Matthew Duncton, Salvador Alvarez, Rao Kolluri, John Ramphal, Sacha Holland
-
Publication number: 20170152247Abstract: Compositions and methods for controlling nematodes are described herein, e.g., nematodes that infest plants or animals. The compounds include oxazoles, oxadiazoles and thiadiazoles.Type: ApplicationFiled: January 25, 2017Publication date: June 1, 2017Applicant: Monsanto Technology LLCInventors: Deryck J. Williams, Matt W. Dimmic, William P. Haakenson, Al Wideman, Barry J. Shortt, Tim Cheeseright, Michael J. Crawford
-
Publication number: 20170152248Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.Type: ApplicationFiled: February 13, 2017Publication date: June 1, 2017Inventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan
-
Publication number: 20170152249Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.Type: ApplicationFiled: June 10, 2016Publication date: June 1, 2017Inventors: Wojciech CZARDYBON, Krzysztof Brzózka, Michal Galezowski, Renata Windak, Mariusz Milik, Magdalena Zawadzka, Pawel Guzik, Ewelina Wincza, Marta Prokop, Katarzyna Wiklik, Aleksandra Sabiniarz, Wieslaw Marek Cholody, Raymond Horvath, Tomasz Rzymski
-
Publication number: 20170152250Abstract: The present invention relates to compounds of formula (I): wherein A1, A2, A3, A4, G1, L, Y1, Y2, Y3, Y4, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to intermediates for preparing compounds of formula (I), to compositions comprising them and to methods of using them to combat and control insect, acarine, nematode and mollusc pests.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Applicant: Syngenta Crop Protection LLCInventors: Jerome Yves CASSAYRE, Peter RENOLD, Myriem EL QACEMI, Thomas PITTERNA, Julie Clementine TOUEG
-
Publication number: 20170152251Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.Type: ApplicationFiled: July 18, 2014Publication date: June 1, 2017Applicants: GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES,INC.Inventors: Soongyu CHOI, Jungsub CHOI, So-Hyun YOON, Yoo Hoon KIM, Jae Yeon KIM, Suk Ho LEE, Young Lag CHO, Ho Young SONG, Dae Yon LEE, Sung Yoon BAEK, Sang Eun CHAE, Tae Kyo PARK, Sung Ho WOO, Yong Zu KIM
-
Publication number: 20170152252Abstract: The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.Type: ApplicationFiled: February 13, 2017Publication date: June 1, 2017Inventors: Mauro Napoletano, Marcello Trevisani, Maria Giovanna Pavani, Francesca Fruttarolo
-
Publication number: 20170152253Abstract: A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(?)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-(?)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(?)-ephedrine from the precipitated salt obtained in step (b).Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Applicant: Janssen Pharmaceuticals, Inc.Inventors: Dominic John Ormerod, Dominique Paul Michel Depre, Andras Horvath
-
Publication number: 20170152254Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl, 5-chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R can be hydrogen, fluoro, or methoxy; R1 can be hydrogen, methoxy, difluoromethoxy, or trifluoromethoxy; and R2 can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: ApplicationFiled: November 29, 2016Publication date: June 1, 2017Applicants: AstraZeneca AB, Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles, Matt Wood
-
Publication number: 20170152255Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.Type: ApplicationFiled: November 29, 2016Publication date: June 1, 2017Applicants: AstraZeneca AB, Cancer Research Technology LimitedInventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
-
Publication number: 20170152256Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.Type: ApplicationFiled: June 4, 2014Publication date: June 1, 2017Applicant: Chiesi Farmaceutici S.p.A.Inventors: Gabriele AMARI, Elisabetta ARMANI, Mauro RICCABONI, Andrea RIZZI, Charles BAKER-GLENN, Wesley BLACKABY, Herve VAN DE POEL, Ben WHITTAKER
-
Publication number: 20170152257Abstract: A phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof was synthesized, which exhibits potent activity as an anticancer agent against, such as breast cancer, lung cancer, and prostate cancer.Type: ApplicationFiled: February 4, 2016Publication date: June 1, 2017Applicant: CHINA MEDICAL UNIVERSITYInventors: TA-HSIEN CHUANG, CHIEN-FU LI, CHIA-CHEN TSAI, CHI-FEN CHANG, CHIEH-YU PENG
-
Publication number: 20170152258Abstract: The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, L, m, p and W are as defined in the specification.Type: ApplicationFiled: December 6, 2013Publication date: June 1, 2017Inventors: Wei-Guo SU, Wei DENG
-
Publication number: 20170152259Abstract: Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or a ring which is formed by 3-9 membered carbocyclic ring fused with benzo ring, and a 4-10 membered heterocyclic ring or a ring which is formed by 4-10 membered heterocyclic ring fused with benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; R1-3 are independently selected from H, F, Cl, Br, I, CN, OH, SH, NH2, CHO, COOH respectively, or selected from the group, optionally substituted by R01, consisting of C1-10 alkyl, C1-10 heteroalkyl, C3-10 cyclohydrocarbyl, C3-10 heterocyclohydrocarbyl, C1-10 alkyl substituted by C3-10 cyclohydrocarbyl or C3-10 heterocyclohydrocarbyl, and C1-10 heteroalkyl substituted by C3-10 cyclohydrocarbyl or C3-10 heterocyclohydrocarbyl.Type: ApplicationFiled: May 18, 2015Publication date: June 1, 2017Inventors: Zhaozhong DING, Guanghua LAI, Shuhui CHEN, Xiaobing YAN
-
Publication number: 20170152260Abstract: Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.Type: ApplicationFiled: December 15, 2016Publication date: June 1, 2017Applicant: Board of Regents, The University of Texas SystemInventors: Jia ZHOU, Haijun CHEN, Qiang SHEN
-
Publication number: 20170152261Abstract: The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG)exp, that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically. 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium, binds the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Specifically, dimeric compounds incorporating two 9-hydroxyellipticine analog structures can even more potently bind the 5?CGG/3?GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Structure-activity relationships (SAR) studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG) repeats, such as r(CGG)exp.Type: ApplicationFiled: January 23, 2017Publication date: June 1, 2017Inventors: Matthew D. Disney, Biao Liu, Jessica L. Childs-Disney, Wang-Yong Yang
-
Publication number: 20170152262Abstract: Provided herein are vinylogous thioester compounds and methods for using the compounds.Type: ApplicationFiled: September 30, 2016Publication date: June 1, 2017Inventors: Yolanda Sanchez, Robert Allaway, Stephanie Bouley, Matthew Wood
-
Publication number: 20170152263Abstract: The present invention provides substituted indazole compound of formula (I) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK4 and/or for the treatment of diseases or disorders induced by IRAK4.Type: ApplicationFiled: June 19, 2015Publication date: June 1, 2017Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20170152264Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.Type: ApplicationFiled: October 20, 2014Publication date: June 1, 2017Applicant: ETERNITY BIOSCIENCE INC.Inventors: Dong LIU, Minsheng ZHANG, Qiyue HU
-
Publication number: 20170152265Abstract: The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.Type: ApplicationFiled: December 7, 2016Publication date: June 1, 2017Inventors: Richard Chesworth, Gerhard Koenig, Amy Ripka, Gideon Shapiro
-
Publication number: 20170152266Abstract: The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxycodone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: ApplicationFiled: November 29, 2015Publication date: June 1, 2017Inventor: John K. Thottathil
-
Publication number: 20170152267Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.Type: ApplicationFiled: August 20, 2013Publication date: June 1, 2017Applicants: DYOMICS GMBH, PIERCE BIOTECHNOLOGY, INC.Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Frank G. Lehmann, Marie Christine Nlend
-
Publication number: 20170152268Abstract: The present invention relates to a novel indene derivative, a preparation method for the same, and a pharmaceutical composition for preventing or treating retinal disease comprising the same as an active ingredient. The novel indene derivative of the present invention, the optical isomer of the same, or the pharmaceutically acceptable salts of the same have excellent inhibitory efficiency of receptor-interacting serine/threonine-protein kinase 1 (RIPK1).Type: ApplicationFiled: January 27, 2017Publication date: June 1, 2017Inventors: Eunhee KIM, Sung-Eun YOO, Nam Sook KANG, Tae-Sung KOO, Min-Young PARK, Young-Hoon KIM, Hyun-Ju BAE, Jin-Woo KIM, Tae-Kyu IN, Choun-Ki JOO
-
Publication number: 20170152269Abstract: The present invention provides a fused bicyclic compound according to formula (H) or a pharmaceutically acceptable salt thereof, wherein L is —S— or —O—; M is —CH?, —N? or —CJ=, wherein J is a non-hydrogen monovalent group; and W, G0 and G1 are independently of each other a non-hydrogen monovalent group. The invention further provides a pharmaceutical composition comprising the compound, a method of synthesizing the compound, a method for inhibiting CDK(s), a method for treating a disease or disorder in a mammal mediated by or associated with cyclin-dependent kinase (CDK), and a use of the compound in the manufacturing of a medicament for treating a CDK-mediated disease or disorder.Type: ApplicationFiled: February 13, 2017Publication date: June 1, 2017Applicant: ANONCO SCIENCES, INC.Inventors: Jin Li, Liu Liu, Minmin Yang
-
Publication number: 20170152270Abstract: A pyridine compound represented by formula (1) that is useful as an insecticide is produced by reacting a compound represented by formula (2) and a compound represented by formula (3). In formula (2) L1 represents a halogen atom; R2, R3, R4, R5, and R6 represent chain hydrocarbon groups, etc., having 1-6 carbon atoms optionally substituted by fluorine atoms; A1 represents —NR7—, an oxygen atom, or a sulfur atom; A2 represents a nitrogen atom or ?CR8—; and R7 and R8 represent C1-6 chain hydrocarbon groups or hydrogen atoms. In formula (3) M+ represents a sodium ion, a potassium ion, or a lithium ion.Type: ApplicationFiled: May 29, 2015Publication date: June 1, 2017Inventors: Takayuki WAKAMATSU, Rika KASAI
-
Publication number: 20170152271Abstract: The present invention relates to the use of a class of novel isothiazolo[4,3-b]pyridine derivatives as well as to pharmaceutical compositions comprising one or more of said isothiazolo[4,3-b]pyridine derivatives and one or more pharmaceutically acceptable excipients as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as viral diseases.Type: ApplicationFiled: July 23, 2015Publication date: June 1, 2017Applicant: Katholieke Universiteit LeuvenInventors: Steven De Jonghe, Piet Herdewyn, Elena Bekerman, Shirit Einav, Gregory Neveu
-
Publication number: 20170152272Abstract: The disclosure provides an improved synthesis for a zinc-lysine complex having the formula [Zn(C6H14N2O2)2Cl]+Cl ?, in which a zinc compound selected from ZnO and ZnCl2, is reacted with a lysine compound selected from lysine and lysineHCl, in aqueous acid. The disclosure also provides oral care and personal care compositions comprising the complex prepared by the synthesis, and methods of using these complexes and compositions.Type: ApplicationFiled: June 18, 2014Publication date: June 1, 2017Applicant: Colgate-Palmolive CompanyInventors: Michael FITZGERALD, Joseph CONVERY, Harsh TRIVEDI, Lisa MANUS
-
Publication number: 20170152273Abstract: Topical pharmaceutical formulations, and methods of treating inflammatory conditions with these formulations, are disclosed.Type: ApplicationFiled: November 30, 2016Publication date: June 1, 2017Applicant: Anacor Pharmaceuticals Inc.Inventors: Tejal Merchant, Dina Jean Coronado, Charles Edward Lee, Delphine Caroline Imbert, Sylvia Zarela Yep
-
Publication number: 20170152274Abstract: Cell binding agent-drug conjugates comprising phosphinate-based charged linkers and methods of using such linkers and conjugates are provided.Type: ApplicationFiled: February 28, 2014Publication date: June 1, 2017Applicant: Hangzhou DAC Biotech Co., Ltd.Inventors: Robert Yongxin ZHAO, Xing LI, Yuangyuang HUANG, Qingliang YANG
-
Publication number: 20170152275Abstract: The present invention relates to a novel compound represented by formula (1), or salt thereof, wherein R is hydroxy group or hydrogen atom; R1 and R2 are the same or different, and are each independently benzyl group which may have a substituent. The present invention provides therapeutically agents, which have remarkable stability against cytidine deaminase, a metabolic enzyme, can be absorbed in vivo by oral administration and inhibit protein synthesis by being incorporated easily into nucleic acid bio-synthesis in vivo for replacing injection agent (5-azacytidine or 2?-deoxy-5-azacytidine) used in clinic for treating myeloma.Type: ApplicationFiled: November 18, 2016Publication date: June 1, 2017Applicant: OHARA PHARMACEUTICAL CO., LTD.Inventors: MAGOICHI SAKO, XIONG LUO
-
Publication number: 20170152276Abstract: Disclosed is a novel tenofovir disoproxil edisylate salt having the structure of Chemical Formula 1.Type: ApplicationFiled: July 9, 2015Publication date: June 1, 2017Applicant: JW Pharmaceutical CorporationInventors: Do-Kyu PYUN, Won-Kyoung LEE, Su-Ha PARK
-
Publication number: 20170152277Abstract: Disclosed herein is a method of forming a thin film. The method includes forming a niobium-containing film by using a niobium precursor composition and a reactant, the niobium precursor composition including a niobium compound represented by Formula (1): Nb(R5Cp)2(L)??Formula (1) (where each R is independently H, a C1 to C6 alkyl group, or R13Si, with each R1 being independently H or a C1 to C6 alkyl group, Cp is a cyclopentadienyl group, and L is selected from among formamidinates (NR, R?-fmd), amidinates (NR, R?, R?-amd), and guanidinates (NR, R?, NR?, R??-gnd)).Type: ApplicationFiled: November 29, 2016Publication date: June 1, 2017Inventors: Jae-soon LIM, Gyu-hee PARK, Youn-joung CHO, Clement LANSALOT, Won-tae NOH, Julien LIEFFRIG, Joo-ho LEE
-
Publication number: 20170152278Abstract: A method of obtaining depolymerized lignin from biomass using a transition metal catalyst and a solvent mixture of organic solvent and water. The invention further relates to a composition obtainable by the method and the production of fuel.Type: ApplicationFiled: November 27, 2014Publication date: June 1, 2017Inventors: Joseph SAMEC, Maxim GALKIN
-
Publication number: 20170152279Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.Type: ApplicationFiled: November 28, 2013Publication date: June 1, 2017Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
-
Publication number: 20170152280Abstract: The present disclosure relates to scaphopetalone analogs, methods of making the analogs, and their uses.Type: ApplicationFiled: September 30, 2016Publication date: June 1, 2017Inventors: Merritt B. Andrus, F. Brent Johnson, Mary Ruth Jaeger Greer, Rex G. Cates
-
Publication number: 20170152281Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: November 10, 2016Publication date: June 1, 2017Applicant: NeurMedix, Inc.Inventors: Steven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
-
NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
Publication number: 20170152282Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: December 18, 2013Publication date: June 1, 2017Applicant: Washington UniversityInventors: Douglas Covey, Albert Jean Robichaud -
Publication number: 20170152283Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.Type: ApplicationFiled: December 6, 2016Publication date: June 1, 2017Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Penn State Research FoundationInventors: Frank J. Gonzalez, Changtao Jiang, Cen Xie, Andrew D. Patterson, Fei Li, James B. Mitchell, Shantu Amin, Dhimant Desai
-
Publication number: 20170152284Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: October 4, 2013Publication date: June 1, 2017Inventor: Douglas F. Covey
-
Publication number: 20170152285Abstract: The present invention is related to an extracting method of kuguacin, pharmaceutical composition comprising the kuguacin and use thereof, specifically related to a use of the kuguacin for treating periodontal diseases.Type: ApplicationFiled: October 4, 2016Publication date: June 1, 2017Applicants: National Taiwan Normal University, Chang Gung Memorial Hospital, KeelungInventors: Po-Jung Tsai, Wen-Cheng Huang, Tzung-Hsun Tsai, How-Ting Ying, Ya-Ling Hung
-
Publication number: 20170152286Abstract: The present disclosure relates to the design and generation of stapled helical peptides that perturb protein-protein interactions (PPIs). The methods disclosed herein for preparing stapled peptides involve providing a peptide having a first amino acid that is functionalized with a salicylaldehyde ester side group and a second amino acid functionalized with a 1,2-hydroxyl amine side group; reacting the first and second amino acids to generate an N,O-benzylidene acetal moiety; and performing acidolysis of the resultant N,O-benzylidene acetal moiety to generate the stapled peptide. In many forms, the stapled helical peptides described herein are not hydrophobic.Type: ApplicationFiled: November 29, 2016Publication date: June 1, 2017Inventors: Xuechen Li, Chi-Lung Lee, Jiaochao Xu